ReviewBrain sciences2025
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.
Review in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.JAMA psychiatry · 2026Trial
- Prenatal and early life phthalate exposure and early life stress: no interactions with adolescent internalizing symptoms.Environment international · 2026Article
- Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression.Journal of medicinal chemistry · 2026Article
- Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.Drug design, development and therapy · 2026Review
- Closed-loop neuromodulation: a paradigm shift in precision neuroscience for clinical and cognitive applications.Frontiers in neuroscience · 2026Review
- Neuroinflammation and treatment resistance in major depressive disorder.Frontiers in pharmacology · 2026Review
- Gepirone for Major Depressive Disorder: From Pharmacokinetics to Clinical Evidence: A Narrative Review.International journal of molecular sciences · 2025Review
- Multimodal evaluation of nitazoxanide as an antidepressant: behavioral, biochemical, and molecular docking insights.Metabolic brain disease · 2025Article
- Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.ACS medicinal chemistry letters · 2025Article
- Special Issue "Depression: From Molecular Basis to Therapy".International journal of molecular sciences · 2025Article
- Novel and emerging anesthetic drugs for the treatments of major depression: a comprehensive review of efficacy, mechanism, and outlook.Frontiers in psychiatry · 2025Review
- Monoamine signaling and neuroinflammation: mechanistic connections and implications for neuropsychiatric disorders.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.